RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EyePoint Pharmaceuticals Stock

EyePoint Pharmaceuticals P/E 2024

EyePoint Pharmaceuticals P/E

-3.09

Ticker

EYPT

ISIN

US30233G2093

WKN

A2QJRU

As of Aug 26, 2024, EyePoint Pharmaceuticals's P/E ratio was -3.09, a -5.79% change from the -3.28 P/E ratio recorded in the previous year.

The EyePoint Pharmaceuticals P/E history

EyePoint Pharmaceuticals Aktienanalyse

What does EyePoint Pharmaceuticals do?

EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering EyePoint Pharmaceuticals's P/E Ratio

The Price to Earnings (P/E) Ratio of EyePoint Pharmaceuticals is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing EyePoint Pharmaceuticals's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of EyePoint Pharmaceuticals is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in EyePoint Pharmaceuticals’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about EyePoint Pharmaceuticals stock

What is the price-to-earnings ratio of EyePoint Pharmaceuticals?

The price-earnings ratio of EyePoint Pharmaceuticals is currently -3.09.

How has the price-earnings ratio of EyePoint Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of EyePoint Pharmaceuticals has increased by -5.79% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of EyePoint Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of EyePoint Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of EyePoint Pharmaceuticals affect the company?

An increase in the price-earnings ratio of EyePoint Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of EyePoint Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of EyePoint Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of EyePoint Pharmaceuticals?

Some factors that influence the price-earnings ratio of EyePoint Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does EyePoint Pharmaceuticals pay?

Over the past 12 months, EyePoint Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyePoint Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of EyePoint Pharmaceuticals?

The current dividend yield of EyePoint Pharmaceuticals is .

When does EyePoint Pharmaceuticals pay dividends?

EyePoint Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of EyePoint Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is EyePoint Pharmaceuticals located?

EyePoint Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyePoint Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyePoint Pharmaceuticals from 8/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did EyePoint Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of EyePoint Pharmaceuticals in the year 2023?

In the year 2023, EyePoint Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyePoint Pharmaceuticals pay out the dividend?

The dividends of EyePoint Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EyePoint Pharmaceuticals

Our stock analysis for EyePoint Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyePoint Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.